JNJ•benzinga•
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Summary
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 18, 2025 by benzinga